Has Shruti Chaturvedi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $456,848 in general payments to Shruti Chaturvedi, MD across 124 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Shruti Chaturvedi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Shruti Chaturvedi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Shruti Chaturvedi, MD

Medical Oncology · Baltimore, MDNPI 1508154345

Payments from drug & device makers

$456,848in general payments, 2019–2025

Across 124 payments — averaging $3684.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$208K
AstraZeneca$87K
Takeda Pharmaceuticals U.S.A., Inc.$72K
Sobi, Inc$50K
Novartis$18K
Bioverativ Therapeutics Inc.$6K
plus $16K from 4 others

What the payments were for

Consulting fees$199,94775%
Speaking & faculty fees$46,36317%
Travel & lodging$17,2286%
Food & beverage$1,8191%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	30	$207,743
AstraZeneca	51	$87,318
Takeda Pharmaceuticals U.S.A., Inc.	18	$72,103
Sobi, Inc	4	$49,598
Novartis	8	$18,069
Bioverativ Therapeutics Inc.	6	$6,410
Dova Pharmaceuticals	2	$6,080
Sanofi-aventis U.S. LLC	3	$5,153
UCB SA	1	$3,000
Kyowa Kirin Co., Ltd	1	$1,374

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CABLIVI$34,419
SOLIRIS$31,935
ULTOMIRIS$31,367
DOPTELET$9,896
NO PRODUCT DISCUSSED$6,290
ADVATE$2,400
PROMACTA$2,025
RECOMBINATE$1,600

How this compares

$456,848 in reported general payments places this provider in the 60th percentile of 180 medical oncology providers in Maryland.

See all medical oncology providers in Maryland →

Medicare billing

Part B allowed, 2024

$17,984

Medicare patients

Services billed

171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XareltoRivaroxaban	17	$16,015
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)	11	$86

Paid to pharmacies, not to this prescriber.

Other medical oncology in Baltimore

Dung leBaltimore$18.7M
Stephanie GaillardBaltimore$12.2M
Ashraf BadrosBaltimore$7.2M
Patrick BrownBaltimore$6.6M
Nilofer AzadBaltimore$6.5M
Jean Hoffman-CensitsBaltimore$5.7M
Ranee MehraBaltimore$5.2M
Michael CarducciBaltimore$4.8M
Tanguy Lim-SeiwertBaltimore$4.6M
Mark LevisBaltimore$4.2M

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →